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ABSTRACT
Recent studies have demonstrated that the Valosin-containing protein (VCP), an ATPase
– associated protein, plays a protective role in the heart against cardiomyopathies and injuries
caused by various cardiac stresses, including ischemia and pressure overload. However, the
underlying molecular mechanisms remain largely unknown. It has been shown that VCP
presents in stressed hearts. Our hypothesis is that VCP plays an essential role in cardiomyocyte
growth and survival through a dual regulatory effect on the signaling of the mechanistic target
of rapamycin (mTOR). Thus, we used a functional gain and loss strategy to determine the
critical role of VCP in regulating mTOR signaling in cardiomyocytes in vitro. By using recombined
adeno-virus system (Ad-CMV-GFP-VCP for overexpression and Ad-U6- siRNA-VCP for
knockdown), we successfully overexpressed VCP and knocked down VCP in H9C2 cells
respectively. This study aimed to better understand how VCP overexpression and knockdown
affected certain proteins involved in the mTOR pathway – in particular phosphorylated Akt
(pAkt T308 and pAkt S473), Raptor, Rictor and mTOR. Western blots were also done to confirm
VCP knockdown and overexpression with GaPDH as the loading control. This preliminary study,
although did not yield substantial results, can be designed as an in vitro system to better
understand VCP and mTOR interactions.
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1. INTRODUCTION
1.1 Cardiomyocyte Growth and Survival, and Heart Diseases
1.1.1 The Character of Cardiomyocytes
The heart is a vital organ that functions as a pump maintaining the blood circulation
around the whole body, which comprises various cellular subtypes, including cardiomyocytes,
fibroblasts, vascular smooth muscle cells (SMCs), endothelial cells, and pericytes; each of them
plays essential roles in physiological and pathological conditions. The main cellular component
of the myocardium is cardiomyocytes (CM), a contractile, excitable heart cell making up cardiac
muscle and driving continuous heart beating, carrying out the cardiac function of the heart by
effectively executing the contraction-relaxation cycle. Morphology, gene expression, and
function of ventricular CMs are different from atrial CMs.
As illustrated in Fig. 1, in human beings and many other animals, cardiomyocytes are the
firstcells to terminally differentiate, thus making the heart one of the first organs to form in a
developing fetus. The postnatal cell cycle withdrawal of CMs shortly after birth and most CMsin
adult hearts are terminally differentiated postmitotic cells exhibiting minimal regenerative
potential. The low turnover rate of cardiomyocytes is problematic because the heart has
insufficient regenerative capacity after injury or in diseased states. For example, a variety of
stimuli, including systemic or regional anoxia or hypoxia caused by acute or chronic myocardial
ischemia, or neurohumoral and mechanical triggers caused by pressure overload, could induce
ventricular cardiomyocyte death through pathways such as necrosis, apoptosis,and possibly
excessive autophagy, resulting in loss of cardiomyocytes in the heart, leading to acute or chronic
heart failure. Thus, it is imperative to better understand the pathogenesis ofvarious cardiac
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disorders to promote cardiomyocyte growth and survival as an effective way not only to treat
but prevent the effects of cardiac injury.

Figure 1: Cell cycle activities in fetal, neonatal, and adult mammalian cardiomyocytes.
In development, the ballooning of the chamber and the further growth of the heart are accomplished by fetal
cardiomyocyte proliferation. After birth, cardiomyocytes gradually stop proliferating and exit the cell cycle (G0/G1
phase). Initially, this arrest is reversible, as newborn cardiomyocytes can re-enter the cell cycle and proliferate
upon injury. Yet during postnatal development, cardiomyocytes undergo one more incomplete cycle, resulting in
binucleated or polyploid neonatal cardiomyocytes. In the case of cell cycle re-entry of adult cardiomyocytes, such
as during pathological hypertrophy in contrast to physiological hypertrophy (e.g., sports and pregnancy), cells
undergo polyploidization, endomitosis, and polynucleation but not cell division. This is a common feature of heart
failure.
Source: Leone M, Magadum A and Engel FB. Cardiomyocyte proliferation in cardiac development and
regeneration: a guide to methodologies and interpretations. American journal of physiology Heart and circulatory
physiology. 2015;309 8:H1237-50.

1.1.2 Cardiomyocyte Hypertrophy and Death in Heart Diseases
Currently, cardiovascular diseases (CVD) account for more than one-third of human
mortalityand is one of the leading causes of death worldwide. Various causes induce cardiac
damage and dysfunction by affecting cardiomyocytes' growth and survival. Due to the unique
character of cardiomyocytes, cardiomyocytes respond to the stimuli distinctively from other
cells in the cell growth and survival. For example, in the presence of physiological or
pathological hemodynamic stress, the heart develops hypertrophy, in which cardiomyocyte is
characterized by increased cell size, instead of an increase in cell number, due to the limited
regenerative capability. In addition, since the heart has minimal repair capacity, it is thus
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susceptible to various stressors leading to cardiomyocyte death, both progressive and acute,
which is a hallmark of various cardiac diseases, including myocardial infarction (MI),
ischemia/reperfusion (IR) and hypertrophic heart failure (HF).
Physiological hypertrophy of the heart, such as a result of exercise or pregnancy, is an
adaptive response to hemodynamic stress, which is believed to be reversible and contributesto
the improvement of cardiac function. However, in pathological stress conditions, such as
hypertension and valvular disease, pathological hypertrophy develops, which is characterizedby
an excessive increase in ventricular dimensions, accompanied by myocardial dysfunction and
fibrosis. Myocardial supply-demand mismatch occurs, secondary to the increased myocardial
oxygen consumption of the hypertrophic heart, which further increases cell death,eventually
leading to the deterioration of cardiac output. Thus, hypertrophy is an independent risk factor
for CVD, including arrhythmias, myocardial infarction, cerebrovascular events, and sudden
death. Thus, pathological ventricular hypertrophy is a predictor of cardiovascular morbidity and
mortality.
Myocardial ischemia, acute or chronic, is the most common cause of cardiomyocyte
death. The disruption in blood flow leading to deficient oxygen supply to cardiac tissue induces
cardiac injury, resulting in irreversible cell necrosis and apoptosis by oxidative stress, calcium
overload, ER stress, and mitochondrial dysfunction, leading to heart failure. Thus, there is an
urgent need to understand the underlying mechanisms of cell death and develop a strategy to
promote cardiomyocyte survival under these diseases.
1.2 Valosin-Containing Protein (VCP) Regulates Cardiac Cell Growth and Survival
Previous studies from my mentor, Dr. Qiu’s lab, have identified VCP as a key
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downstream mediator of cardiomyocyte growth and survival, although the mechanisms are yet
unknown1. This novel gene was shown to be delicately involved in numerous known cell growth
and survival mechanisms. More importantly, it selectively ameliorated the diseased state with
little to no effects at baseline 2. Our study seeks to further characterize the cardioprotective
mechanisms of VCP, which may lead to a better therapeutic avenue for patients with heart
diseases.
1.2.1 Molecular Character of VCP and its Biological Roles
VCP/p97 (also called Cdc48 in yeast and plants) is a hexameric ATPase protein belonging
to type II AAA (ATPases associated with various cellular Activities) ATPase family and is
ubiquitously expressed in all cells, 2 and responsible for mediating protein homeostasis3. Its
structure, shown in Fig. 2, contains a conserved N-terminal domain (1-187) followed by two
copies of the AAA domains, D1 (209-460) and D2 (481-761) and a C terminal domain (762806)4. By interacting with adaptor proteins, VCP is involved in a number of cellular activities,
including cell cycle control, transcriptional regulation, apoptosis, protein degradation, and
stress responses 5-12. It plays a major role in the endoplasmic reticulum- associated degradation
where it extracts ubiquitinated proteins from the ER and maintains their misfolded state until
proteasomal proteins can degrade them. Increased expression of VCP correlates with growth
and survival of cancer cells13-15. Specific genetic mutations of VCP areassociated with
multisystem disorders in muscle, brain and bone and with other diseases suchas Alzheimer’s
disease, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS) 16-19, though theunderlying
mechanisms are not fully understood. Inhibition of VCP activity, therefore, has a range of
consequences for the cell, beginning with the accumulation of misfolded, polyubiquitinated
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proteins and culminating in apoptosis, often triggered by ER stress and theunfolded protein
response 3,20.

Figure 2: Structure of the AAA-ATPase Cdc48p/VCP.
Domain structure of Cdc48p/VCP. Cdc48p/VCP consists of four domains, the N-terminal domain (N), the ATPase
domains D1 and D2 comprising the motifs Walker A, Walker B and the 'second region of homology' (SRH) motif,
and the C-terminal domain (C). In Cdc48p/VCP the major ATPase activity is located in the D2 domain, whereas the
D1 domain is responsible for oligomerization. The N-terminal domain is involved in the binding of substrates and
cofactors.
Source: Braun, R. (2006). Functional Proteome Analysis of Pathophysiological Variants of the AAA-ATPase
Cdc48p/VCP.

1.2.2 Identification of VCP in the Heart.
VCP was first identified VCP in the heart when it was shown that it acts as a novel
downstreameffector of the cardioprotective signaling mechanism conferred by Hsp22 1. Initial
studies in vitro showed that VCP represents the link between Hsp22-mediated activation of Akt
and nuclear factor-kappa B (NF-ĸB)-induced expression of iNOS in cardiac myocytes, thereby
playing a central role in the mechanisms of cardiac cell survival promoted by Hsp22. 2dimensional electrophoresis followed by mass spectrometry was used to isolate and identify
potential proteins which interact with Hsp22 and Akt in the peri-nuclear area (Fig. 3).

Figure 3: Identification of VCP in the heart.
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A. Representative two-dimensional gel electrophoresis with 8% polyacrylamide gels in a pH range 3-10, using
nuclear fractions from hearts of WT and Hsp22 TG mice. The VCPspot is circled. B. Quantitation of VCP expression in
total protein extracts. α-actinin used as a loading control, n=3 per group.
Source: Lizano P, Rashed E, Kang H, et al. Cardiovasc Res. 2013;99(4):685-693. 2.3. VCP and cardiomyocytes
survival and growth.

Proteins were first separated based on their isoelectric points, and then further
separated based on their size. Proteins that were differentially expressed in Wild-type (WT) and
Hsp22 Transgenic (TG) samples were marked, cut out of the gel, and then identified by mass
spectrometry. Importantly, VCP was upregulated in Hsp22 samples compared to WT.
Coimmunoprecipitation was then used to determine whether there were any
interactions between VCP, Akt, and Hsp22. Remarkably, the data revealed that VCP interacts
with both Hsp22 and Akt, suggesting that they form a complex.
1.2.3 Cardiac Protection of VCP in Pathological Conditions.
VCP has been proven to be crucial to various cellular processes such as membrane
fusion, transcriptional activation, and cell cycle progression 21, as VCP is abundantly present in
cardiactissue, and its role in various heart diseases in being continuously established. Imbalance
in protein homeostasis is a hallmark of many cardiac diseases like myocardial infarction, heart
failure, and diabetic cardiomyopathy. 22 As one of VCP’s primary roles is maintaining
proteostasis, it is thought that VCP may play a protective role in cardiovascular pathological
conditions.
A. VCP Protects Cardiomyocytes Against Induced Cell Death and Hypertrophy In Vitro.
Previous studies showed that overexpression of VCP protected isolated cardiomyocytesagainst
apoptosis as measured by TUNEL, in vitro (Fig. 4)1. Lizano et al1 showed that VCP activates NFkB, AKT and STAT3 and increases iNOS expression in a dose-response manner. VCP
overexpression reduced chelerythrine apoptosis of cardiomyocytes by 50%, and these effects
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were eliminated by the addition of the Akt inhibitor, NF-kB inhibitor STAT3 inhibitor, and iNOS
inhibitor. Thus, VCP protects cardiomyocytes against apoptotic death by promoting
STAT3/AKT/NF-kB/INOS signaling. Other studies have shown that overexpression of VCP
reduces cardiac hypertrophy in vitro. 2

Figure 4: VCP resists cell death in isolated cardiomyocytes.
Apoptosis measured by TUNEL in vehicle-treated (open bars) vs. chelerythrine-treated (closed bars) cardiac
myocytes, upon over-expression of VCP in the presenceof NF-kB inhibitor (SN50), pan-NOS inhibitor (L-NNA), and
specific iNOS inhibitors (AG, 1400W) compared with vehicle. *p <0.05 vs. same group without chelerythrine;
#P<0.05 vs. corresponding β-Gal control.
Source: Lizano P, Rashed E, Kang H, et al. Cardiovasc Res. 2013;99(4):685-693.

B. VCP Protects Ischemia-Reperfusion Injury in the Mouse Heart In Vivo.
Ischemia/Reperfusion (IR) is a cardiovascular disease characterized by the deficiency ofoxygen
supply to the heart (ischemic phase) followed by restoration of regular blood flow (reperfusion
phase), both of which cause irreparable damage to cardiac tissue. Ischemic preconditioning, a
process by which the myocardium produces endogenous nitrous oxide (NO) and regulates
contraction/dilation, is known to protect the myocardial tissue from extensive damage caused
by IR injury. 23 Inducible NO synthase (iNOS) is the main mediator in NO synthesis, making it a
vital part of ischemic preconditioning.
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Based upon results obtained in vitro, the physiological relevance of VCP was tested in
vivo bygenerating a cardiac-specific VCP TG mouse, overexpressing VCP by 3-4 folds. These TG
miceand their WT littermates were anesthetized, and the left anterior descending arteries
occluded for 45 minutes to induce ischemia followed by 24 hours of reperfusion (Fig. 5). The
areas at risk (AAR) of infarct were determined using retrograde injection of Alcian blue through
the aorta which highlights areas of reduced blood flow, and the infarcts measured after 15minute incubation of Triphenyl tetrazolium chloride (TTC). Although the areas at risk were
similar, as shown in Fig.5, VCP overexpression reduced infarct size by 50% compared to WT,
highlighting VCP’s cardioprotective role24.

Figure 5: Overexpression of VCP reduces myocardial infarct size in TG mice.
(a) Schema of the ischemia/reperfusion protocol. (b) Representative staining of left ventricle by Alcian blue and
Triphenyl Tetrazolium Chloride (TTC). (c) Quantitation of AAR/LV and IS/AAR in WT and TG mouse hearts (n = 5 for
TGand 7 for WT group). Data are the mean ± SEM. **p = 0.0006 vs. WT. from Lizano et al 2017
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Source: Lizano, P., Rashed, E., Stoll, S., Zhou, N., Wen, H., Hays, T. T., Qin, G., Xie, L.-H., Depre, C., & Qiu, H. (2017).
The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo.
Scientific reports, 7, 46324-46324. https://doi.org/10.1038/srep46324

C. VCP Protects Pressure Overload-Induced Cardiac Hypertrophy and Apoptosis. VCP
also protects the heart from pressure overload-induced hypertrophy (Fig. 6)2. VCP TG mice and
their WT littermates were anesthetized, and their transverse aortas isolated.Transverse aortic
constriction (TAC) was performed by tying a 27-gauge needle to the aorta and then removing
the needle, leaving behind the knot. Sham-operated mice did not receive the constriction.
Hearts were excised and measured, and cardiomyocyte size determined by wheat germ
agglutinin (WGA) staining (Fig. 6A). As expected, WT mice that underwent TAC experienced
cardiac hypertrophy unlike WT sham mice as evidenced by increased left ventricular weight
compared to tibia length (Fig. 6B), heart weight compared to body weight(Fig. 6C), and crosssectional area (Fig. 6D). WGA staining revealed that the cardiomyocytes were enlarged in WT
TAC hearts compared to sham control (Fig. 6D). Importantly, VCP TG TAC mice did not show
significant differences to sham controls. In fact, VCP TG TAC hearts exhibited similar
measurements to both VCP TG sham controls and WT sham controls,highlighting VCP’s
cardioprotective abilities while not affecting cardiomyocyte size at baseline. Further
experiments showed that TAC-induced cell apoptosis was significantlyattenuated in the TAC TG
mice compared to TAC WT mice, as measured by TUNEL assay (Fig.6E). Thus, VCP promotes cell
growth and survival under pathological conditions in TG mice.
Additionally, several regulatory mechanisms have been implicated in pressure overloadinduced cardiac hypertrophy. Two major mechanisms are mechanical stretch-induced and
neurohumoral stimulation-induced hypertrophic and gene responses in cardiomyocytes. VCP
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appears to play a role in both. Firstly, mechanical stretch-induced reprogramming of fetal
genes, a known mechanism of LVH, is inhibited by VCP, thus attenuating the cardiac response to
pressure overload. Secondly, in AngII-induced hypertrophic cardiomyocytes, VCP is
downregulated in a dose- and time-dependent manner, and VCP overexpression prevented
AngII-induced alterations. 2

Figure 6: VCP reduces hypertrophy during pressure overload.
A. Examples of WT and VCP TG heart massand cardiomyocyte size stained by wheat germ agglutinin (WGA) in
Sham and Transverse Aortic Constriction (TAC) animals. B. Left ventricles (LV) weight/tibial length ratio (TL). C.
Heart weight/body weight ratio (HW/BW). D. The cross-sectional area (CSA) of cardiomyocytes. E. Quantitative
analysis of apoptotic cardiomyocytes by TUNEL assay. *P < 0.01 vs. sham, #P < 0.01 vs. WT TAC mice. n = 4–
5/group. Data are shown as mean ± SEM, two-way ANOVA was used.
Source: Zhou N, Ma B, Stoll S, Hays TT, Qiu H. The valosin-containing protein is a novel repressor of cardiomyocyte
hypertrophy induced by pressure overload. Aging Cell. 2017;16(5):1168-1179

1.2.4 Potential Molecular Mechanisms Underlying VCP-Mediated Cardiomyocyte
Growth and Survival
A. VCP Regulates ER/Mitochondrial Functions. The endoplasmic reticulum (ER) is the
largest organelle of the cell and is responsible for protein synthesis and folding, posttranslational modifications and regulating transmembraneproteins. The sarcoplasmic reticulum
(SR) is a morphologically distinct variation of the ER present especially in muscle cells and is
specialized for Ca2+ release to aid in muscle
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contraction. 25 VCP is a ubiquitin-selective protein and plays an essential role in
maintaining ER integrity by interacting with E3 ubiquitin ligases such as ERAD-associated HRD
(HRD1) andglycoprotein78 (gp78). VCP is responsible not only for the regulation of the activity
of variousfactors, but also the delivery of misfolded proteins for proteasomal degradation. The
ER interacts with the mitochondria, and VCP plays a key role in extracting misfolded proteins
from the mitochondria for mitochondria-associated degradation and in mitochondrial
autophagy. Thus, due to the essential roles it plays in cellular functions, impairment of VCP
activity can lead to ER and mitochondrial dysfunction, as illustrated in Fig. 7. 26

Figure 7: VCP and ER/Mitochondria.
Summary of the common features related to VCP in different diseases.Despite the fact that the cofactors and the
regulatory signalling pathways underlying the pathogenesis of thesedisorders may vary, VCP could promote stressinduced misfolded protein degradation and maintain calcium homeostasis, which subsequently helps resist
ER/mitochondrial stress-induced cell damage and death. As theincrease of VCP in cancer cells would protect cells
against death, the deficiency of VCP in neurodegenerativedisorders and heart diseases would induce cell damage
and death, due to the loss of these functions. (The red arrows represent the promotive effects and green arrows
stand for the inhibitory/suppressive effects).
Source: Sun, X., & Qiu, H. (2020). Valosin-Containing Protein, a Calcium-Associated ATPase Protein, in Endoplasmic
Reticulum and Mitochondrial Function and Its Implications for Diseases. Int J Mol Sci, 21(11).
https://doi.org/10.3390/ijms21113842

Studies have shown that VCP regulation of mitochondrial activity was dependent on
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iNOS, with VCP overexpression protecting against IR injury by promoting iNOS activity and in
turn improving mitochondrial function. However, VCP inhibitor KUS121 increases ATP
production,reduces ER stress, improves mitochondrial function, and attenuates IR injury. 27
These contradictory results might be due to varied method of activation and inhibition of VCP
activity and supports evidence that the effect of VCP on iNOS is dose dependent.
B. VCP Regulates mTOR Signaling in the Heart. Multiple signaling pathways have been
found to be involved in cardiac hypertrophy and survival under pathological conditions28-31. The
mechanistic target of rapamycin (mTOR), a key nutrient/energy/redox sensor and controller of
protein synthesis, has been demonstratedas one of the critical signaling mechanisms involved in
cardiac growth, based on the strong experimental evidence that inhibitors of mTOR, such as
rapamycin, reduced pathological hypertrophy32-36. mTOR is an atypical serine/threonine protein
kinase that executes many cellular functions through interaction with various adaptor proteins
to form two complex multiprotein complexes, mTORC1 and mTORC2. The mTOR pathway plays
a vital role in regulating cellular homeostasis and stress response. mTORC1 is a master regulator
of proteinsynthesis, and cell growth and proliferation, while mTORC2 regulates cell survival and
polarity34, 37-39.
Through loss of function studies of various mTOR pathway components, animal models
haveindicated that mTOR is critical to embryonic cardiovascular development and has a hand in
key cellular processes required for regular postnatal growth and maintenance of cardiac
function. It has been studied that mTOR mainly exerts its function mainly through the
formation of the protein complexes. So far, mTORC1 is known to constitute the proteins
Raptor, mLST8, PRAS40, DEPTOR, and Tt1/Tel2, while mTORC2 contains mTOR, scaffold
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protein Rictor, SIN1, PROTOR, mLST8, DEPTOR and Tt1/Tel2. Additionally, the Akt and AMPK
pathways are the most well characterized regulators of mTORC1. Similarly, for mTORC2, Akt
that is phosphorylated at serine 473 (pAKT S473) is the best-known substrate.34
mTOR knockout mice show massive apoptosis, fibrosis, autophagy, mitochondrial
dysfunction and sarcomere disarray, finally resulting in death 8 weeks after tamoxifen-induced
gene deletion. 40 Inducible cardiac-specific mTOR deletion in adulthood leads to chamber
dilation and wall thinning, eventually leading to cardiac dysfunction and heart failure.
The previous studies in my mentor’s lab 41 showed that VCP plays a dual role in the
regulationof mTOR – it activates the survival-promoting mTORC2 by repressing stress inducedgrowth promoting mTORC1 (Fig. 8). During pressure-overload, VCP reduction was accompanied
by the increase in phosphorylation of Akt at threonine 308 (pAKT T308) and elevated mTORC1
activity in LVH in TAC mice. Overexpression of VCP in the TAC VCP TG mice suppressed this
pathway. Akt is a kinase protein and VCP, which lacks any phosphorylation abilities, has been
studied to promote Akt phosphorylation under physiological conditions. Additionally, VCP is
activated by Akt in persistent hypoxic stress conditions, and Akt works downstream of
mTORC2. In VCP TG mice, mTORC2 is upregulated by VCP overexpression, which in turn
promotes Akt phosphorylation. Thus, interactions between Akt and VCP is both direct and
indirect, and given the key role Akt plays in cellular processes, better understanding of these
interactions could help further reveal the role of VCP in cardiac hypertrophy. 22
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Figure 8: Overexpression of VCP significantly repressed the transverse aortic constriction (TAC)-induced
activation of the AKT/mTORC1/S6K pathway.
(A) The protein level of VCP in the hearts of WT and VCP TG mice at baseline and after 2-week TAC. (B) Western
blots of proteins of PI3K, AKTs, and mTORC1 signalling in the LV tissues after 2-week TAC compared to sham in
both WT and VCP TG mice. GAPDH is a loading control for total protein. *P < 0.01 vs. sham, #P < 0.01 vs. WT TAC
mice. n = 4/group. Data are shownas mean ± SEM, two-way ANOVA was used.
Source: Zhou, N., Stoll, S., & Qiu, H. (2017). VCP represses pathological cardiac hypertrophy. Aging (AlbanyNY),
9(12), 2469-2470. https://doi.org/10.18632/aging.101357.

Additionally, VCP suppressed mTORC1 only under the stress of TAC but not at baseline
physiological conditions. Thus, the selective effects of VCP in regulating mTORC1 and mTORC2is
unique compared to other regulators of the mTOR pathway and highlights the clinical
significance of VCP due to the ability to affect pathological conditions without impairing
physiological growth and function. (Fig. 9)41

VCP IN CARDIOMYOCYTE SURVIVAL AND GROWTH

24

Figure 9: An illustration of the mechanism by which valosin-containing protein (VCP) protects left ventricular
hypertrophy (LVH) against pressure overload.
Pressure overload reduces VCP expression in heart which activates mTORC2 and attenuates the inhibitive effect of
VCP on AKT/mTORC1/S6K signalling, subsequently promotes the pro-growth pathway. VCP TG restores the TACsuppressed VCP and represses the TAC-induced activation of AKT/mTORC1/S6K, fetal gene upregulation, and
collagen synthesis and thus protects the heart against TAC-induced LVH.
Source: Zhou, N., Stoll, S., & Qiu, H. (2017). VCP represses pathological cardiac hypertrophy. Aging (Albany NY),
9(12), 2469-2470. https://doi.org/10.18632/aging.101357

Although great progress has been made in elucidating the complex regulation and
function ofmTOR signaling networks, many aspects of the pathophysiology of mTOR signaling in
heart still remain unknown. For example, although the mTORC1 pathway has been extensively
investigated, the regulation of mTORC2 is poorly understood, and the identified regulators of
mTORC2 are few34. It is difficult to completely understand the full function of mTOR signalingin
the heart without precisely ruling out the involvement of mTORC2 in these mechanisms. In
addition, it has been shown that mTORC1 is not only responsible for the maladaptive cardiac
hypertrophy but is also necessary for physiological cardiac growth. Thus, inhibition of mTORC1
not only attenuates the pathological response but may also affect its physiological effects34.
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Furthermore, prolonged pharmacological treatment, such as rapamycin, disrupts both mTORC1
and mTORC2, causing unexpected side effects, which limit its use in human 34, 35, 37. Therefore,
the approach which selectively inhibit the maladaptive functions of mTORC1without impairing
the normal functions of mTORC2 may lead to newer, safer therapies.
2. SPECIFIC AIMS
VCP has been known to interact with the mTOR pathway, and both play crucial roles in
normalfunctioning of the heart and during cardiac pathologies. During certain cardiac
pathologies, VCP levels are either increased or dramatically decreased, which contributes to cell
death, and in turn, the mTOR pathway is affected. We are particularly interested in the
regulation of VCP on mTOR signaling for the following reasons: 1) mTOR signaling is a wellknown key pathway involved in cardiac growth and survival34, but the mechanisms have not
been fully understood. 2) The regulation of mTORC2 in the heart remains unclear despite its
importance29,34. Our preliminary data indicate that VCP is likely a mediator of mTORC2, whichis
not characterized yet; 3) VCP presents as a unique regulator of mTOR which differs from other
mTOR inhibitors34. The overall goal of the study is to determine how the proteins involved in
the mTOR pathway are affected by differences in VCP levels in cardiomyocytes invitro, to
support in vivo studies observed in disease condition and in VCP TG mice.
Based on the previous findings, our hypothesis, as summarized in Fig. 10 is that VCP acts
as aunique dual regulator of mTOR by selectively activating survival complex mTORC2 but
inhibiting growth-promoting complex mTORC1.
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Figure 10: Diagrammatic representation of the hypothesis that VCP plays a dual regulatory role in mTOR
signaling.
Red arrows show inhibitory effects while green arrows show promotive effects.

We proposed to test the hypothesis through the following two specific aims:
Aim 1: To determine how overexpression of VCP affects mTOR signaling in
cardiomyocytes, in terms of the expression and activity of mTOR, its adaptor proteins and
downstream signaling of mTORC1 and C2.
Aim 2: To determine whether VCP is necessary for the regulation of mTOR signaling by
knocking down VCP in cardiomyocytes
3. METHODS
3.1 Cell Culture
H9C2 cells are cardiomyocytes originally derived from embryonic rat ventricular tissue
and iscommonly used in cardiovascular research. Cryopreserved H9C2 cell vials were rapidly
thawed as per instructions for 2 minutes at 37C and the contents quickly transferred to a 15mL
tube and centrifuged at 900 rpm for 5 minutes at 22C. The supernatant was discarded,and the
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pellet resuspended in 2 mL of Dulbecco’s modified eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 2% penicillin/streptomycin and cultured in total 8-9mL of
media in Corning 100mm dishes at 37C in a humidified atmosphereof 5% CO2. Cells were fed
every 3-4 days and sub-cultured at a 1:4 ratio when they reached >80% confluency. For the
adenoviral infection, the cells were plated to achieve an average cell yield of 5.5x106 cells/mL.
3.2 Construct of Adenovirus
A. VCP Adenovirus (Ad-VCP, Vector Biolabs), Fig. 11
Construct: Ad-GFP-h-VCP
Backbone: Adenoviral – Human Type 5 (dE1/E3)
Promoter: CMV
Transgene: human VCPReporter/Tag: eGFP
PFU Titer: 4x1010 PFU/mLControl used: Ad-Gal

Figure 11: Backbone of Ad-VCP.
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B. VCP shRNA silencing adenovirus (Ad-shRNA VCP), Fig. 12
Construct: Ad-h-VCP-shRNA
Backbone: Adenoviral – Human Type 5 (dE1/E3)
Promoter: U6
Reporter/Tag: eGFP
PFU Titer: 2.30x1010 PFU/mL
Control used: Ad-Scramble

Figure 12: Backbone of Ad-siRNA-VCP.

3.3 Infection of Cultured Cells
For overexpression, H9C2 cells were infected with VCP adenovirus (Ad-VCP) conjugated
to GFP (green fluorescent protein). The experiment was first optimized using different
multiplicity of infection (MO (0,10,20,40,100,200) of the virus and 50 MOI was used for all
consecutive experiments for 48 hours and was imaged after 24 hours to confirm successful
infection. For knockout, the cells were infected with VCP shRNA adenovirus (Ad-shRNA VCP)
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conjugated to GFP, and the experiment was optimized with various MOI as with the Ad-VCP.For
all further experiments, 5 MOI of the virus was used for 4 days. Cells were imaged after 48
hours to confirm successful infection. Cells infected with Ad-CMV-BGal was used as controlfor
overexpression and those infected with Ad-U6-Scramble were used as control for knockout.
(Fig. 13)

Figure 13: Summary of experimental methods used for cell culture, infection and western blot.

3.4 Western Blot
H9C2 cells were trypsinized, centrifuged at 900rpm for 5 min at 4C and the pellet
washed with 1mL cold PBS. After washing, the supernatant was discarded, and the pellet stored
at - 80C until further use. The cells were then resuspended in 80ul of RIPA lysis buffer and kept
on ice for 15-20minutes. They were then centrifuged at 13000rpm for 15 min at 4C and the
supernatant was transferred to a new tube. Protein contents were measured using the
Bradford assay with Bovine Serum Albumin (BSA) as the standard. Equivalent amounts of
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protein (15ug) were calculated and made up to 20ul with LDS sample buffer, 10x reducing agent
and double distilled (DD) water. The samples were denatured at 95C for 5 minutes andthen
loaded onto a 10 well, 8% Novex Pre-cast Gel with 5ul of Precision Protein Plus molecularweight
markers in the first well. The gel was run at 130V for 45 minutes and electrophoretically
transferred to a Nitrocellulose membrane. After blocking with Intercept Blocking Buffer (Li-Cor)
for 1 hour at room temperature, the membrane was incubated in theprimary antibody at 4C
overnight. (Fig. 14)

Figure 14: Diagrammatic representation of Western blots and the proteins involved in mTOR signaling studied in
this project.

The antibodies used were: VCP monoclonal antibody (1:5000), rabbit GaPDH (1:5000),
rabbitmTOR mAb (1:3000), rabbit Raptor mAb (1:5000), rabbit Rictor (1:5000), rabbit pAkt T308
mAb (1:3000), and rabbit pAkt S473 (1:3000). Membranes were incubated with goat antimouse (imaged at 680nm) or donkey anti-rabbit (imaged at 720nm) secondary antibodies
(1:10000) as appropriate for 1 hour at room temperature and imaged with the LI-COR Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
4. RESULTS
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4.1 Optimization of Adenoviral MOI for VCP Knockdown
H9C2 cells were infected with different MOIs (0,10,20,40,100,200) of the Ad-siRNA-VCP
virusand imaged to reflect GFP expression in cell. Images were taken after 48 hours, as shown
in Fig. 15A, using the Li-Cor Odyssey System at 10x magnification. The increase in green as the
MOI increases shows that more cells have successfully taken up the virus. However, confluency
of the pictured culture was higher than desired, and fewer cells were seeded for the following
experiments to achieve a final cell count of around 5.5x106 cells per 10cm2 dish.A western blot
was done (Fig. 15B) with VCP monoclonal antibody to show a dose-dependentdecrease in VCP
levels in the cells. As VCP expression was highly reduced for higher MOIs, an MOI of 5 was used
for subsequent experiments.
A
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B

Figure 15: Dose-response of Ad-siRNA-VCP in H9C2 cells.
A. Image of GFP in the infected cells with differentMOI of virus. B. Western blot showing the VCP expression in the
infected cells to optimize MOI of Ad-siRNA-VCP

4.2 Optimization of Adenoviral MOI for VCP overexpression
As with the Ad-siRNA-VCP viral infection, H9C2 cells were infected with different
MOIs(0,10,20,40,100,200) of the Ad-VCP virus and imaged after 48 hours (Fig. 16). Images were
taken using the Li-Cor Odyssey system at 10x magnification to reflect GFP expression within the
cells. 50 MOI of the virus was used for all succeeding experiments.
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Figure 16: Optimization of Ad-VCP dose in H9C2 cells.
Image of cells expressing different MOI of virus images under microscope 48 hours post transfection.

4.3 Western Blot to Confirm Functional Loss/Gain Model
A western blot was done using 8% Novex Pre-Cast Gel to confirm VCP knockdown and
overexpression in H9C2 cells infected with Ad-shRNA-VCP and Ad-VCP respectively. Although
Fig. 17 shows a clear decrease and increase in VCP expression upon knockdown and
overexpression respectively, the control used in this experiment was uninfected cells, and thus,
no substantial claims of knockdown/overexpression efficiency can be made.
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Figure 17: Western blot showing VCP knockdown and overexpression.
Levels of VCP in H9C2 cells infected withAd-siRNA-VCP and Ad-VCP were tested using a western blot. The control
used here was uninfected H9C2 cells. GaPDH was used as loading control.

4.4 VCP and GaPDH Observed Only in the Controls
A western blot was run using the wet transfer method to reduce possibility of protein
degradation and VCP and GaPDH protein levels were measured (Fig. 18). It was observed that
while the two controls (Ad-BGal and Ad-Scramble) showed bands for both VCP and GaPDH, the
lack of bands for GaPDH in samples (infected with Ad-siRNA-VCP and Ad-VCP) indicates issues
arising either from experimental technique, or due to protein degradation (as sampleswere
stored in -20C for two weeks before the experiment was conducted).

Figure 18: Western blot for functional loss/gain model validation.
A. Western blot showing expression of VCP in cells. B. Western blot showing expression of GaPDH, commonly used
as loading control.
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4.5 Interaction Between VCP and Proteins Involved in mTOR Signaling
To determine whether any changes occurred in the levels of mTOR, Raptor (required for
formation of mTORC1), and Rictor (required for formation of mTORC2) with VCP
knockdown/overexpression, another western blot was run using 10% Novex Pre-Cast Gel
followed by wet transfer in 4C for 3 hours. While controls showed some expression of mTOR
(Fig. 19A) and Raptor (Fig. 19B), this was consistent with the blots for VCP/GaPDH and thus, no
substantial conclusion about interactions can be made. No bands were observed for Rictor.(Fig.
19C).
A western blot was run using 10% Novex Pre-Cast gel followed by semi-dry transfer for
45 minutes, to determine levels of pAkt T308 (involved in the mTORC1 pathway) and pAkt S473
(involved in the mTORC2 pathway). pAkt has a molecular weight of around 56kDa. The blot for
pAkt S473 (Fig. 19E) showed bands around 56kDa, but no definite conclusion can be made.On the
other hand, for pAkt T308 (Fig. 19D), unspecific bands around 25kDa were observed and was
possibly due to errors in sample loading and/or experimental techniques.
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Figure 19: Western blot showing expression of various proteins involved in the mTOR pathway.
A. Membraneincubated with mTOR rabbit mAb. Bands were observed for controls (labeled 2 and 4) at 280 kDa. B.
Membraneincubated with Raptor rabbit mAb, with bands observed at 149kDa for controls (labeled 2 and 4). C.
Membraneincubated with Rictor rabbit mAb. D. Membrane incubated with pAkt T308 rabbit mAb, with unspecific
bands observed at around 30 kDa. E. Membrane incubated with pAkt S473, bands observed at 56 kDa. All
membraneswere incubated with goat anti-rabbit secondary antibodies and imaged at 520nm.

5. DISCUSSION/TROUBLESHOOTING
The main aims of this study were to study the effects of VCP knockdown and
overexpressionon mTOR signaling pathway-related proteins in H9C2 cells by measuring protein
levels in infected cells using the western blotting technique. The aims were based on the
hypothesis that VCP plays a unique dual role in regulating mTOR by selectively inhibiting growth
promoting complex mTORC1 while activating survival complex mTORC2, based on previous
findings. By understanding the specific mechanisms involved in cardioprotection by VCP,
strategies to prevent and treat various heart diseases can be formed.
The first part of the study was to optimize MOI of adenoviral infection for both VCP
overexpression (Ad-VCP) and knockdown (Ad-siRNA-VCP) in order to establish conditions for
accurate results. The process took longer than anticipated due to time constraints, and in the
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future optimization will be further required to improve results. H9C2 cells were used as they are
an established in vitro model for various cardiovascular diseases like ventricular hypertrophy
and cardiomyopathies. These cells are commonly used in place of primary cardiomyocytes as
they recapitulate hypoxic and hypertrophic environments. However, H9C2cells deviate from
cardiomyocytes in several ways, the primary being that their morphology and gene expression
patterns are closer to resembling primary skeletal myoblasts thanprimary cardiomyocytes.
Additionally, in response to hypertrophic stimuli, they do not show sarcomeric reorganization,
nor do they beat spontaneously in culture. However, for this study, the characteristics of H9C2
cells are sufficiently similar to primary cardiomyocytes andthus are an effective model to use.
The limitations of the model must still be taken into consideration. Further studies can use
primary neonatal cardiomocytes to study the molecular mechanisms involved in the interaction
between VCP and the various proteins involved in the mTOR pathway.
For the western blot run to optimize MOI of Ad-siRNA-VCP virus required for adequate
knockdown of VCP, a comparison can be made between images taken that show increasingly
higher amounts of GFP and therefore higher percentage of infection and the VCP levels in the
blot, showing that there is a dose-dependent decrease of VCP as MOI of virus used increases.
However, an ideal experiment should have included controls like GaPDH or GFP in the same
western blot membrane to confirm that the decrease in VCP levels was due to efficient
knockdown and not due to differences in protein loading in the wells. Interestingly, Fig 14
shows a decrease in GaPDH levels in VCP overexpression. It is possible that VCP’s dosedependent interaction with iNOS increased cellular toxicity and that VCP is no longer
cardioprotective at a dosage of 50MOI of the Ad-VCP virus. Thus, future experiments will needto
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try alternative loading controls while also better optimizing the dosage and duration of viral
infection.
The second part of the project focused on studying the interaction between VCP and
variousproteins involved in the mTOR pathway. Akt is a downstream protein involved in the
pathway,with pAkt T308 being a substrate for mTORC1 and pAkt S473 for mTORC2. Although
bands were slightly visible for pAkt S473, it is possible that the membrane was cut too close to
the molecular weight of the protein to allow for acceptable conclusions to be drawn. For the
membrane blotted with pAkt T308 antibody, non-specific bands were observed around 2530kDa suggesting errors in experimental methods.
The other proteins tested were Raptor (involved in formation of mTORC1), Rictor
(involved information of mTORC2) and mTOR. The first few western blots showed no results for
these proteins, possibly because the semi-dry transfer technique used was causing them to
degradebefore they could be incubated with their respective antibodies. For the final blot, the
wet transfer technique was used so as to preserve the integrity of the proteins and yielded
betterresults. Clear bands were visible for Raptor and mTOR for both the controls Ad-Scramble
andAd-gal but were either faint or not visible for the two samples. When the same
membraneswere incubated with VCP and GaPDH antibodies, a similar pattern was observed
thus suggesting that there were issues with sample loading and that the bands for the samples
were not representative of the actual protein levels in the cells. It is also possible that the
proteins in the samples degraded as they had been stored at -20C for nearly two weeks before
the final experiment was conducted.
Thus, no evident conclusions can be made from this study, owing to time constraints

VCP IN CARDIOMYOCYTE SURVIVAL AND GROWTH

39

and errors in experimental technique. However, the project optimized the first step of the
processand troubleshooting the issues faced later will be helpful in future endeavors. The project
alsohighlighted the need to better understand the molecular mechanisms behind the role of
VCPin cardioprotection and its interaction with various pathways like the mTOR pathway.
6. FUTURE DIRECTION
Better understanding the role of VCP and its involvement in cardioprotection is
essential. In the future, elucidating these mechanisms is important, especially in the context of
VCP’s interaction with the mTOR pathway which is the scope of this current project.
In the future, we will interrogate the molecular mechanisms underlying the selective
effects of VCP on mTORC1 and mTORC2, in terms of the specific subcellular shuttling, proteinproteininteraction and the crosstalk between mTORC1 and mTORC2. Secondly, we will
determine the transcriptional mechanism by which VCP regulates mTOR signaling, e.g., VCPmediated transcription factors (TFs) and gene networks/pathways. Additionally, as miRNA is a
well- known, powerful negative regulator of gene expression, and has been linked to the
regulationof mTOR in other tissues42, we will also determine the VCP-regulated miRNAs.
Furthermore, we will further define the domain-dependent regulatory mechanisms. Finally, we
will elucidate the physiological relevance and the underlying mechanisms of VCP in the heart at
baseline and under stress.
Based on our preliminary data and previous publications, we strongly believe that our
proposed studies will elucidate the specific mechanisms involved in cardioprotection by VCP
under cardiac stress which will provide a new strategy for preventing and possibly treating
heart failure.
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7. SUMMARY
Cardiovascular diseases are one of the leading causes of mortality around the world,
and there is a constant need to better understand mechanisms involved so as to strategize new
and more effective preventative and therapeutic solutions. Recent studies have highlighted the
role of VCP in protecting the heart again various cardiomyopathies and injuries that are caused
by cardiac stresses like ischemia and pressure overload, among others. Understandingthis
mechanism at the molecular level is imperative, along with elucidating the mechanisms with
which VCP interacts with various key pathways in the heart.
The hypothesis of this project was that VCP plays an essential role in cardiomyocyte
growth and survival by exerting a dual regulatory effect on mTOR signaling. Using a functional
gain/loss strategy model, we aimed to better understand the interactions between VCP and
some of the critical proteins involved in the mTOR pathway. By using recombinant adeno-viral
systems, we successfully knocked down (using Ad-siRNA-VCP) and overexpressed VCP (usingAdVCP) in H9C2 cells and confirmed the same using a western blot. Although no substantial
conclusions can be made from the data obtained, these preliminary studies combined with
previously published studies can be used to better understand the role of VCP in cardiomyocyte
growth and survival through its interactions with mTOR.
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